FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury
February 22, 2024 07:53 ET
|
SeaStar Medical Holding Corporation
SCD-PED (Pediatric) is the first FDA-approved product in the Company’s Quelimmune™ product family DENVER, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...
SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology
February 01, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Feb. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market
January 26, 2024 08:05 ET
|
SeaStar Medical Holding Corporation
DENVER, Jan. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (the “Company”), a medical technology company developing proprietary solutions to reduce the consequences...
SeaStar Medical Appoints David A. Green as Chief Financial Officer
January 11, 2024 16:05 ET
|
SeaStar Medical Holding Corporation
DENVER, Jan. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
January 09, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Jan. 09, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
December 28, 2023 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Dec. 28, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts
December 13, 2023 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated...
SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 14, 2023 16:04 ET
|
SeaStar Medical Holding Corporation
DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
FDA Issues Approvable Letter for SeaStar Medical’s Selective Cytopheretic Device for Pediatric Patients
October 30, 2023 08:00 ET
|
SeaStar Medical Holding Corporation
DENVER, Oct. 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated...
FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome
October 18, 2023 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Oct. 18, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...